Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets,
Translating Microbiome R&D into Improved Healthcare Outcomes & Commercial Potential
Building on 7 years of success, the 8th Antigen-Specific Immune Tolerance Summit is back - the only conference dedicated to advancing curative th
Editor's Picks
